PMID- 22950641
OWN - NLM
STAT- MEDLINE
DCOM- 20130307
LR  - 20151119
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Linking)
VI  - 34
IP  - 9
DP  - 2012
TI  - The effects of vitamin E-coated membrane dialyzer compared to simvastatin in 
      patients on chronic hemodialysis.
PG  - 1135-9
LID - 10.3109/0886022X.2012.717484 [doi]
AB  - BACKGROUND: We investigated the effects of the use of vitamin E-coated membrane 
      (VEM) dialyzer in comparison to simvastatin on markers of chronic inflammation, 
      oxidative stress, and endothelial cell apoptosis in ten patients on chronic 
      hemodialysis (HD), aiming at distinguishing the different treatment effects and 
      their time sequence on these pathogenetic routes. METHODS: Ten HD patients were 
      sequentially submitted to a 6-month treatment with the use of VEM and 10 mg of 
      simvastatin daily, interrupted by a 3-month washout period. At baseline, at 3, 
      and 6 months of each trial, serum C-reactive protein (CRP), apolipoprotein (Apo) 
      A1 and B, lipoprotein-a [Lp(a)], high-sensitivity interleukin-6 (hsIL-6), 
      monocyte chemoattractant protein-1 (MCP-1), soluble intercellular adhesion 
      molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), 
      soluble E-selectin (sE-selectin), soluble Fas (sFas), soluble Fas ligand (sFasL), 
      and plasma oxidized low-density lipoproteins (oxLDL) levels were determined. 
      RESULTS: VEM treatment resulted in a significant decrease in CRP, IL-6, sICAM-1 
      at 3 months, and oxLDL at 6 months, compared to baseline. Simvastatin resulted in 
      a significant decrease in CRP, which correlated with decreases in both total (r = 
      0.87, p < 0.05) and low-density lipoprotein cholesterol, IL-6, sICAM-1, sVCAM-1, 
      oxLDL, and sFas at 6 months, compared to baseline. Simvastatin effects on sVCAM-1 
      (mean difference = 652 ng/mL; 95% CI = 294 to 2686; p < 0.05) and sFas (mean 
      difference = 1284 pg/mL; 95% CI = 510 to 1910; p < 0.05) differed significantly 
      from the corresponding VEM effects. CONCLUSIONS: The 6-month use of VEM resulted 
      in more direct and immediate anti-inflammatory effects compared with those caused 
      by the 6-month treatment with simvastatin. Simvastatin caused a more intense 
      decrease in the markers of inflammation, which was in part correlated with its 
      lipid-lowering effects.
FAU - Kirmizis, Dimitrios
AU  - Kirmizis D
AD  - Department of Nephrology, Hippokration General Hospital, Aristotle University, 
      Thessaloniki, Greece. dkirmizis@yahoo.co.uk
FAU - Papagianni, Aikaterini
AU  - Papagianni A
FAU - Dogrammatzi, Fani
AU  - Dogrammatzi F
FAU - Belechri, Anna-Maria
AU  - Belechri AM
FAU - Alexopoulos, Efstathios
AU  - Alexopoulos E
FAU - Efstratiadis, Georgios
AU  - Efstratiadis G
FAU - Memmos, Dimitrios
AU  - Memmos D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20120906
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 
      (2-(2,6-dichloro-4-((3-furan-2-ylacryloylamino)methyl)benzoylamino)-3-((thiazolidine-4-carbonyl)amino)propionic 
      acid)
RN  - 0 (Acrylamides)
RN  - 0 (Antioxidants)
RN  - 0 (Biomarkers)
RN  - 0 (Coated Materials, Biocompatible)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Interleukin-6)
RN  - 0 (Membranes, Artificial)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 1406-18-4 (Vitamin E)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - AGG2FN16EV (Simvastatin)
SB  - IM
MH  - Acrylamides/blood
MH  - Aged
MH  - Antioxidants/pharmacology
MH  - Biomarkers/blood
MH  - C-Reactive Protein/drug effects/metabolism
MH  - *Coated Materials, Biocompatible
MH  - Cross-Over Studies
MH  - Equipment Design
MH  - Female
MH  - Follow-Up Studies
MH  - Glomerular Filtration Rate/drug effects
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology
MH  - Inflammation/blood/etiology/*prevention & control
MH  - Interleukin-6/blood
MH  - Kidney Failure, Chronic/blood/complications/*therapy
MH  - Male
MH  - *Membranes, Artificial
MH  - Middle Aged
MH  - Oxidative Stress/drug effects
MH  - Renal Dialysis/*instrumentation
MH  - Simvastatin/*pharmacology
MH  - Treatment Outcome
MH  - Vitamin E/*pharmacology
MH  - beta-Alanine/analogs & derivatives/blood/drug effects
EDAT- 2012/09/07 06:00
MHDA- 2013/03/08 06:00
CRDT- 2012/09/07 06:00
PHST- 2012/09/07 06:00 [entrez]
PHST- 2012/09/07 06:00 [pubmed]
PHST- 2013/03/08 06:00 [medline]
AID - 10.3109/0886022X.2012.717484 [doi]
PST - ppublish
SO  - Ren Fail. 2012;34(9):1135-9. doi: 10.3109/0886022X.2012.717484. Epub 2012 Sep 6.